EP4125824A4 - A sachet formulation comprising metformin and dapagliflozin - Google Patents

A sachet formulation comprising metformin and dapagliflozin Download PDF

Info

Publication number
EP4125824A4
EP4125824A4 EP21776477.8A EP21776477A EP4125824A4 EP 4125824 A4 EP4125824 A4 EP 4125824A4 EP 21776477 A EP21776477 A EP 21776477A EP 4125824 A4 EP4125824 A4 EP 4125824A4
Authority
EP
European Patent Office
Prior art keywords
dapagliflozin
metformin
sachet formulation
sachet
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21776477.8A
Other languages
German (de)
French (fr)
Other versions
EP4125824A1 (en
Inventor
Abdullah TASKIN
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4125824A1 publication Critical patent/EP4125824A1/en
Publication of EP4125824A4 publication Critical patent/EP4125824A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP21776477.8A 2020-03-27 2021-01-15 A sachet formulation comprising metformin and dapagliflozin Pending EP4125824A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/04809A TR202004809A2 (en) 2020-03-27 2020-03-27 A sachet formulation comprising metformin and dapagliflozin
PCT/TR2021/050029 WO2021194446A1 (en) 2020-03-27 2021-01-15 A sachet formulation comprising metformin and dapagliflozin

Publications (2)

Publication Number Publication Date
EP4125824A1 EP4125824A1 (en) 2023-02-08
EP4125824A4 true EP4125824A4 (en) 2023-12-27

Family

ID=77892783

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21776477.8A Pending EP4125824A4 (en) 2020-03-27 2021-01-15 A sachet formulation comprising metformin and dapagliflozin

Country Status (3)

Country Link
EP (1) EP4125824A4 (en)
TR (1) TR202004809A2 (en)
WO (1) WO2021194446A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10360924A1 (en) * 2003-12-23 2005-07-28 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Composition containing metformin, useful as antidiabetic, is formulated as water-soluble granules for administration, after dissolution, through a gastric tube
US20130034606A1 (en) * 2009-11-13 2013-02-07 Astrazeneca Uk Limited Immediate release tablet formulations
WO2013077825A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
CN103462900A (en) * 2013-09-02 2013-12-25 天津市聚星康华医药科技有限公司 Metformin hydrochloride dry suspension and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077822A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic New formulations for treatment of diabetes
MX2018011696A (en) * 2016-03-31 2019-06-06 Lupin Ltd Pharmaceutical composition of dapagliflozin.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10360924A1 (en) * 2003-12-23 2005-07-28 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Composition containing metformin, useful as antidiabetic, is formulated as water-soluble granules for administration, after dissolution, through a gastric tube
US20130034606A1 (en) * 2009-11-13 2013-02-07 Astrazeneca Uk Limited Immediate release tablet formulations
WO2013077825A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
CN103462900A (en) * 2013-09-02 2013-12-25 天津市聚星康华医药科技有限公司 Metformin hydrochloride dry suspension and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021194446A1 *

Also Published As

Publication number Publication date
EP4125824A1 (en) 2023-02-08
TR202004809A2 (en) 2021-10-21
WO2021194446A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
EP4114460A4 (en) Vaccines against sars-cov-2 and other coronaviruses
EP4105211A4 (en) Pyrimidoheterocyclic compounds and application thereof
EP4101852A4 (en) Pyridopyrimidinone compound and application thereof
EP4051246A4 (en) Bilayer tablet formulations comprising dapagliflozin and metformin
EP4132529A4 (en) Compounds and uses thereof
EP3985014A4 (en) Romo1-derived antimicrobial peptides and variants thereof
EP4096667A4 (en) Compounds and uses thereof
EP3976014A4 (en) A combination comprising alogliptin and metformin
EP3981769A4 (en) Pyrrolopyrimidine compound and use thereof
EP4097096A4 (en) Compounds and uses thereof
EP4096651A4 (en) Compounds and uses thereof
EP4028385A4 (en) Usp30 inhibitors and uses thereof
EP4151636A4 (en) Pyrrolidine compound and use thereof
EP4110066A4 (en) Formulations and uses thereof
EP4159734A4 (en) Fluoropyrrolopyridine compound and application thereof
EP3927779A4 (en) Antimicrobial azo compounds and uses thereof
EP4019521A4 (en) Azaheteroaryl compound and application thereof
EP3784672A4 (en) Tablet formulations comprising metformin and sitagliptin
EP4112047A4 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
EP4025194A4 (en) A combination comprising vildagliptin and metformin
EP4125824A4 (en) A sachet formulation comprising metformin and dapagliflozin
EP4121031A4 (en) 3-diarylmethylenes and uses thereof
EP4031122A4 (en) Effervescent tablet formulations comprising dapagliflozin and metformin
EP4129064A4 (en) Novel antibacterial peptide and use thereof
EP4112642A4 (en) Anti-cd137 construct and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

A4 Supplementary search report drawn up and despatched

Effective date: 20231127

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/12 20060101ALI20231121BHEP

Ipc: A61K 47/02 20060101ALI20231121BHEP

Ipc: A61K 31/70 20060101ALI20231121BHEP

Ipc: A61K 9/16 20060101ALI20231121BHEP

Ipc: A61K 9/00 20060101ALI20231121BHEP

Ipc: A61P 3/10 20060101ALI20231121BHEP

Ipc: A61K 31/351 20060101ALI20231121BHEP

Ipc: A61K 31/155 20060101ALI20231121BHEP

Ipc: A61K 9/20 20060101AFI20231121BHEP